NeOnc’s Delivery may Finally Change the Equation for Brain Cancer’s Next Frontier

Phase 2a data for NEO100 in IDH1-mutant high-grade glioma show a promising signal and set up FDA discussions on a potential path forward.

Rhea-AI Summary

NeOnc Technologies Holdings (NTHI) reported Phase 2a data for its intranasal brain cancer therapy NEO100 in recurrent or progressive Grade III/IV IDH1-mutant glioma. The study showed six-month progression-free survival of 48.9% versus a prespecified 20% benchmark, with a reported p-value of 0.0047. Median overall survival was 26.09 months, and 5 of 24 patients remained on treatment at data cutoff, with no major toxicities and mostly low-grade adverse events.

The company aims to pursue a targeted development path in this biomarker-defined population and plans to seek a Type B FDA meeting to discuss a potential registrational pathway. The NEO100 data suggest a clinical signal that may warrant a larger, better-controlled trial and could support broader interest in intranasal “nose-to-brain” delivery approaches.

Positive

• Six-month PFS 48.9% vs prespecified 20% benchmark (p=0.0047) in Phase 2a
• Median overall survival 26.09 months in 24-patient Phase 2a cohort
• No major toxicities reported; adverse events mainly low-grade across the cohort
• 5 of 24 patients still on NEO100 treatment at data cutoff
• Plans to seek Type B FDA meeting on potential registrational pathway

Negative

• Phase 2a data from a small 24-patient cohort, requiring confirmation in larger controlled trials
• Highly competitive glioblastoma landscape with numerous active trials and prior late-stage failures

Argus 15 min delay

+3.75% vs previous close $3.45 last price 0.9x rel. volume Open Argus

Details

Market Reaction – NTHI

$3.31 $3.48 Day Range

$99.52M Market Cap

Following this news, NTHI has gained 3.75%, reflecting a moderate positive market reaction. Our momentum scanner has triggered 3 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $3.45.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

On Sep 21, NTHI posted a 2.15% 24-hour gain after reporting the same NEO100 Phase 2a readout; this a...

Analysis

On Sep 21, NTHI posted a 2.15% 24-hour gain after reporting the same NEO100 Phase 2a readout; this article reiterates the progression-free survival, survival and safety findings while noting the proposed FDA Type B meeting.

Key Figures

Six-month progression-free survival: 48.9% P-value: 0.0047 Median overall survival: 26.09 months +1 more

Six-month progression-free survival

48.9%

Phase 2a study vs. 20% prespecified benchmark

P-value

0.0047

Phase 2a progression-free survival analysis

Median overall survival

26.09 months

Phase 2a study

Patients remaining on treatment

5 of 24 patients

At the data cutoff

Historical Context

1 past event · Latest: Sep 21

1 event

1. Sep 21

   Phase 2a data

   24h Move

   +2.1%

   NEO100 reported positive progression-free survival and overall-survival results

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

blood-brain barrier, intranasal delivery, progression-free survival, p-value, +1 more

5 terms

blood-brain barrier medical

"solve the blood-brain barrier problem by forcing a conventional systemic drug"

A protective barrier of tightly packed cells and supporting tissue that controls what substances in the blood can enter the brain, acting like a security checkpoint that keeps out most pathogens and many drugs while allowing essential nutrients through. For investors, the barrier matters because whether a therapy can cross or safely bypass it often determines clinical success, regulatory approval and commercial potential for treatments of brain disorders.

intranasal delivery medical

"NEO100 uses an intranasal delivery approach designed to reach the central nervous system"

A method of giving a drug or vaccine through the nose using sprays, drops, or inhaled particles so the medicine is absorbed by nasal tissues and can enter the bloodstream or reach the brain more directly than an oral pill. Investors care because intranasal delivery can speed onset, avoid needles, lower manufacturing or distribution costs, and open new markets for treatments that are hard to administer by mouth or injection—factors that affect a product's commercial potential and regulatory path.

progression-free survival medical

"reported six-month progression-free survival of 48.9% versus a prespecified 20% benchmark"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

p-value technical

"with a reported p-value of 0.0047"

A p-value is a number that helps determine how likely it is that a result or pattern happened by chance rather than because of a real effect. For investors, a low p-value suggests that the findings in a study or analysis are probably meaningful and not just random noise—like noticing a pattern in coin flips that’s unlikely to occur by chance. This helps in assessing the reliability of information used to make financial decisions.

type b meeting regulatory

"plans to seek a Type B meeting with the FDA"

A Type B meeting is a formal, scheduled discussion between a drug or medical-device developer and a health regulator to resolve key mid‑ or late‑stage development issues such as clinical trial plans, interpretation of results, or steps needed for approval. Like a mid‑project review with an inspector, the meeting’s outcome can meaningfully change the timeline, cost and risk for a candidate: a clear, positive outcome lowers uncertainty for investors, while requests for more data or changes can signal delays and extra expense.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com)– NeOnc Technologies Holdings (NASDAQ: NTHI) is becoming a prominent player, as brain cancer research is entering an increasingly sophisticated era.

However, one of the field’s biggest problems remains stubbornly simple: getting effective therapy to the tumor while protecting the brain from additional damage. A July 2026 review in Science Translational Medicine described glioblastoma as remaining one of the most aggressive adult brain cancers, with survival still largely unchanged despite advances in molecular diagnostics and supportive care. At the same time, researchers are pursuing an expanding menu of approaches; targeted therapies, immunotherapy, tumor-treating fields, focused delivery technologies and molecularly selected treatments.

One of the most important developments has been the increasing use of molecular biomarkers to divide brain tumors into more precisely defined diseases. The FDA's recent brain-tumor approvals illustrate the trend: therapies are increasingly being developed around specific molecular alterations rather than treating every tumor as biologically identical. Vorasidenib, for example, targets susceptible IDH1/IDH2-mutant tumors, while other recent approvals have focused on specific alterations in pediatric brain cancers.

That is where NeOnc enters the story with NEO100. Rather than attempting to solve the blood-brain barrier problem by forcing a conventional systemic drug through it, NEO100 uses an intranasal delivery approach designed to reach the central nervous system through the nasal/olfactory pathway. The company's Phase 2a study specifically enrolled patients with recurrent or progressive Grade III and Grade IV glioma carrying an IDH1 mutation; a biomarker-defined population where the company is attempting to establish a targeted development path.

The August 2026 Phase 2a readout gives investors and researchers a reason to pay attention, while also demanding caution. NeOnc reported six-month progression-free survival of 48.9% versus a prespecified 20% benchmark, with a reported p-value of 0.0047. Median overall survival was 26.09 months, and five of 24 patients remained on treatment at the data cutoff. The company also reported no major toxicities across the cohort, with adverse events predominantly low-grade.

The appropriate takeaway being that NEO100 generated a clinical signal worthy of further investigation.

The broader competitive landscape underscores both the opportunity and the challenge. The National Cancer Institute currently lists numerous active glioblastoma trials involving combinations of chemotherapy, radiation, immunotherapy, targeted agents, tumor-treating fields and other experimental approaches. Meanwhile, Novocure's Phase 3 TRIDENT study did not meet its primary endpoint for overall survival when tumor-treating fields were initiated earlier, illustrating how difficult it remains to translate promising therapeutic concepts into statistically conclusive clinical benefits.

For NeOnc, the next major question is therefore whether the NEO100 signal can be reproduced in a larger, better-controlled study. The company says it plans to seek a Type B meeting with the FDA to discuss a potential registrational pathway for recurrent IDH1-mutant high-grade glioma. That regulatory discussion could help clarify what evidence would be required for the program's next stage.

The bigger significance of NEO100 may ultimately extend beyond a single drug. If intranasal delivery can demonstrate that therapeutically meaningful exposure to the brain can be achieved while maintaining tolerability, it could strengthen interest in the nose-to-brain delivery concept itself.

About 24/7 Market News

In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication.  Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What patient population was enrolled in NeOnc's Phase 2a trial of NEO100?

The Phase 2a study enrolled patients with recurrent or progressive Grade III and Grade IV glioma carrying an IDH1 mutation, creating a biomarker-defined population for a targeted development path.

What is distinctive about NEO100’s delivery approach for brain tumors?

NEO100 uses an intranasal delivery approach designed to reach the central nervous system via the nasal/olfactory pathway, aiming to address the blood-brain barrier challenge without forcing a conventional systemic drug through it.

What are NeOnc’s planned next regulatory steps for NEO100?

The company plans to seek a Type B meeting with the FDA to discuss a potential registrational pathway for NEO100 in recurrent IDH1-mutant high-grade glioma, which could clarify what evidence is needed for the program’s next stage.